Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of first-line osimertinib plus locally ablative radiotherapy in synchronous oligometastatic EGFR-mutant non-small cell lung cancer
2020-004114-35Phase 2Completed
- Sponsor
- European Thoracic Oncology Platform
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by European Thoracic Oncology Platform. Primary endpoints: Proportion of patients with grade 2 or higher pneumonitis requiring medical treatment and Progression-free survival. Started Oct 2021; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-004114-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004114-35.